Full Description
Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The availability of these novel formulations to once-inaccessible areas of the body has greatly expanded the therapeutic window of existing drug molecules. Nanoparticulate drug delivery highlights and examines the transition of nanoparticulate drug delivery systems from the laboratory into a commercially viable sector. The first chapters of the book provide an overview of the use and characterization of nanoparticulate systems as drug carriers, including the assessment of their morphology, sterility and potential toxicity. In the latter part of the book, chapters cover nanotoxicology, regulatory aspect and clinical trials, ending with an overview of several case studies and a look towards future developments.
Contents
List of figuresList of tablesForewordChapter 1: Nanoparticulate systems as drug carriers: the needAbstract:1.1 Introduction: nanoparticles for drug delivery1.2 Need: solubility, bioavailability, targeting and more1.3 Specific nanoparticulate strategies for overcoming solubility and bioavailability limitationsChapter 2: Nanoparticles as drug carriersAbstract:2.1 Nanoparticles as drug carriers: the scope2.2 Nanoparticles as drug delivery carriers2.3 Application areas for nanoparticulate drug delivery systems2.4 Routes of administration of nanoparticulate drug delivery systems2.5 ConclusionChapter 3: Characterization techniques for nanoparticulate carriersAbstract:3.1 Need and challenges for characterization techniques of nanoparticulate drug carriers3.2 Measuring the size of nanoparticles3.3 Zeta potential measurement [1, 4]3.4 Characterizing the morphology of the nanoparticles3.5 Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles [46, 47]3.6 Toxicity evaluation of nanoparticles3.7 Evaluating immunological potential of nanoparticlesChapter 4: Nanotoxicology: evaluating toxicity potential of drug-nanoparticlesAbstract:4.1 Nanotoxicology: need towards developing safe and sustainable drug delivery systems4.2 In vitro assays for assessing toxicity of nanoparticles4.3 In-vivo assays for assessing toxicity of nanoparticles4.4 Genotoxicity evaluationChapter 5: Regulatory aspects of nanoparticulate drug delivery systemsAbstract:5.1 Nanoparticulate drug carriers: the regulatory facet5.2 Issues associated with regulating nano-drug delivery systems5.3 Current approaches for regulating pharmaceutical nanocarriersChapter 6: Clinical trials industrial aspectsAbstract:6.1 Clinical trials of nanoparticulate drug delivery systems: successes and failures6.2 Case studies: cancer6.3 Case studies: other diseases6.4 Nanoparticulate drug delivery: an industrial outlookChapter 7: Case studies: nano-systems in the marketAbstract:7.1 Case studies: performance and market approval7.2 Are nano or conventional drug delivery systems a better choice? - a market overview7.3 Future perspectives on nanoparticulate drug carriersIndex
